{"id":"concomitant-antibiotic-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, diarrhea)"},{"rate":null,"effect":"Allergic reactions"},{"rate":null,"effect":"Drug-drug interactions"},{"rate":null,"effect":"Photosensitivity (if fluoroquinolone-containing)"}]},"_chembl":{"chemblId":"CHEMBL606111","moleculeType":"Small molecule","molecularWeight":"1040.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach combines antibiotics with distinct mechanisms of action (e.g., beta-lactams, fluoroquinolones, macrolides) to provide synergistic bacterial killing and minimize the development of antibiotic resistance. By attacking pathogens at multiple biochemical pathways simultaneously, concomitant therapy increases the likelihood of bacterial eradication and reduces treatment failure rates. This strategy is particularly valuable in serious infections where monotherapy may be insufficient or resistance is a concern.","oneSentence":"Concomitant antibiotic therapy works by simultaneously administering multiple antibiotics to target bacteria through different mechanisms, reducing resistance and improving treatment efficacy.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:23.532Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections (specific indication dependent on Phase 3 trial design)"}]},"trialDetails":[{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06087536","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex","status":"RECRUITING","sponsor":"Omnix Medical Ltd","startDate":"2026-03","conditions":"Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia","enrollment":54},{"nctId":"NCT06765135","phase":"NA","title":"Point of Care Respiratory Pathogen Testing for Antibiotic Stewardship in Primary Care","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pennsylvania","startDate":"2025-02-01","conditions":"Upper Respiratory Infection","enrollment":8000},{"nctId":"NCT03594487","phase":"PHASE1","title":"Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis","status":"TERMINATED","sponsor":"Jeffrey Gelfand","startDate":"2018-11-16","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":5},{"nctId":"NCT07221708","phase":"PHASE2, PHASE3","title":"Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-03-01","conditions":"Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium","enrollment":200},{"nctId":"NCT07270523","phase":"NA","title":"Therapeutic Monitoring of Beta-lactams in Critically Ill Patients With Sepsis","status":"NOT_YET_RECRUITING","sponsor":"Complexo Hospitalario Universitario de A Coruña","startDate":"2026-01-01","conditions":"Bacterial Sepsis","enrollment":198},{"nctId":"NCT07230041","phase":"","title":"In Vivo Antibiotics Removal During Hemoadsorption Cartridges and Continuous Renal Replacement Therapy in the Intensive Care Unit","status":"RECRUITING","sponsor":"Niguarda Hospital","startDate":"2025-01-15","conditions":"Septic Shock","enrollment":20},{"nctId":"NCT06841705","phase":"PHASE2","title":"Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial","status":"RECRUITING","sponsor":"Shilpa Grover, MD, MPH","startDate":"2025-07-15","conditions":"Immune Checkpoint Inhibitor-Related Colitis","enrollment":80},{"nctId":"NCT06443502","phase":"PHASE3","title":"A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-19","conditions":"Pouchitis","enrollment":30},{"nctId":"NCT04332848","phase":"PHASE4","title":"Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-07-28","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT06859866","phase":"NA","title":"Efficacy of Adjunctive At-Home Photodynamic Therapy (aPDT) in the Treatment of Peri-Implant Mucositis","status":"RECRUITING","sponsor":"Koite Health Oy","startDate":"2025-04-29","conditions":"Peri-implant Mucositis","enrollment":30},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT05499481","phase":"PHASE3","title":"Short Against Long Antibiotic Therapy for Infected Orthopedic Sites","status":"COMPLETED","sponsor":"Balgrist University Hospital","startDate":"2022-09-15","conditions":"Orthopedic Devices Associated With Misadventures, Infection, Surgical Site, Antibiotic Side Effect","enrollment":495},{"nctId":"NCT01463540","phase":"PHASE4","title":"Gastrostomy Tube Placed After Gastropexy Versus Gastrostomy Tube Placed Using the Traditional Push/Pull Techniques","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2010-09","conditions":"Gastrostomy, Methods","enrollment":206},{"nctId":"NCT06731881","phase":"NA","title":"Assessing the Efficacy of Photodynamic Therapy for Preventing Surgical Site Infections","status":"RECRUITING","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2025-06-04","conditions":"Surgery, Nasal Disease, Light; Therapy, Complications","enrollment":80},{"nctId":"NCT06916390","phase":"PHASE4","title":"GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2025-09-30","conditions":"Pouchitis","enrollment":20},{"nctId":"NCT05427136","phase":"","title":"Early Pulmonary Dysfunction in Childhood Cancer Patients","status":"RECRUITING","sponsor":"University Children's Hospital Basel","startDate":"2021-06-01","conditions":"Pulmonary Dysfunction","enrollment":140},{"nctId":"NCT06310941","phase":"NA","title":"Mechanical Insufflation-exsufflation and Hypertonic Saline in Nosocomial Bacterial Respiratory Tract Infection","status":"NOT_YET_RECRUITING","sponsor":"Hospital San Carlos, Madrid","startDate":"2026-01-01","conditions":"Nosocomial Infection, Nosocomial Pneumonia, Tracheobronchitis","enrollment":100},{"nctId":"NCT06861725","phase":"NA","title":"CARIES ARREST USING SILVER DIAMINE FLUORIDE VERSUS FISSURE SEALANT in OCCLUSAL DENTAL CARIOUS LESIONS: RANDOMIZED CONTROLLED TRIAL","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-04-01","conditions":"Dental Caries, Caries Arrested, Silver Diamine Fluoride","enrollment":76},{"nctId":"NCT04323553","phase":"","title":"Comparison of Pulsed-field Gel Electrophoresis and Whole Genome Sequencing to Determine Transmission Rate of ESBL-producing E.Coli","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-03-06","conditions":"Analysis Transmission Rate","enrollment":43},{"nctId":"NCT04098133","phase":"","title":"Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-08-22","conditions":"Infections With CPB","enrollment":100},{"nctId":"NCT04089345","phase":"PHASE3","title":"Stelara fOr ChRonic AntibioTic rEfractory pouchitiS","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-06-15","conditions":"Pouchitis","enrollment":20},{"nctId":"NCT02591472","phase":"NA","title":"An Integrated-Delivery-of-Care Approach to Improve Patient Outcomes, Safety, Well-Being After Orthopaedic Trauma","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-01-11","conditions":"Musculoskeletal Injury Trauma","enrollment":88},{"nctId":"NCT05444218","phase":"NA","title":"Surgical Access Combined With Systematically Administered Antibiotics in the Treatment of Peri-implantitis","status":"COMPLETED","sponsor":"University of Guarulhos","startDate":"2021-05-01","conditions":"Peri-Implantitis","enrollment":89},{"nctId":"NCT02538991","phase":"NA","title":"TVT Versus Bulkamid®-Injections in Treatment of Stress Urinary Incontinence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2015-09","conditions":"Urinary Stress Incontinence","enrollment":224},{"nctId":"NCT04200651","phase":"PHASE4","title":"Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery","status":"TERMINATED","sponsor":"The New York Eye Surgery Center","startDate":"2020-01-13","conditions":"Glaucoma, Cataract","enrollment":25},{"nctId":"NCT06093360","phase":"","title":"Flapless Surgical Treatment of Peri-implantitis","status":"COMPLETED","sponsor":"Universidad Complutense de Madrid","startDate":"2018-01-01","conditions":"Peri-Implantitis","enrollment":117},{"nctId":"NCT00621192","phase":"PHASE1, PHASE2","title":"Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections","status":"COMPLETED","sponsor":"The Emmes Company, LLC","startDate":"2008-06","conditions":"Necrotizing Enterocolitis, Intra-abdominal Infection","enrollment":200},{"nctId":"NCT03909698","phase":"","title":"Antibiotic Dosing in Patients on Intermittent Hemodialysis","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2016-09-15","conditions":"Kidney Failure, Chronic, Antibiotics, Hemodialysis","enrollment":150},{"nctId":"NCT03558984","phase":"PHASE3","title":"D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery","status":"TERMINATED","sponsor":"PolyPid Ltd.","startDate":"2019-12-17","conditions":"Surgical Site Infection, Sternal Infection, Cardiac Surgery","enrollment":2},{"nctId":"NCT05564156","phase":"NA","title":"Development and Evaluation of Clinical Pharmacy Services in Respiratory Diseases","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2020-06-30","conditions":"Pneumonia, COPD Asthma, COPD Exacerbation","enrollment":168},{"nctId":"NCT02951481","phase":"","title":"Antimicrobial Stewardship Program for Clostridium Difficile Infection.","status":"COMPLETED","sponsor":"José María Aguado García, MD, PhD","startDate":"2017-02-15","conditions":"Clostridium Difficile, Enterocolitis, Pseudomembranous","enrollment":403},{"nctId":"NCT02692651","phase":"PHASE4","title":"A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-05-01","conditions":"Clostridium Difficile Infection (CDI)","enrollment":144},{"nctId":"NCT05126121","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Xiuli Zuo","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT05133193","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT05014373","phase":"PHASE3","title":"Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19","status":"UNKNOWN","sponsor":"University of the Philippines","startDate":"2020-10-12","conditions":"Covid19","enrollment":144},{"nctId":"NCT04991584","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-08-04","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT04781569","phase":"","title":"Staphylococcus Aureus Caught in Action at the Site of Infection","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-06-06","conditions":"Staphylococcus (S.) Aureus Infection","enrollment":100},{"nctId":"NCT03226626","phase":"PHASE2, PHASE3","title":"Tumescent Anesthesia Antibiotic Delivery (TAAD)","status":"UNKNOWN","sponsor":"HK Surgical, Inc.","startDate":"2021-12-01","conditions":"Surgical Site Infection, Thrombosis, Sepsis","enrollment":330},{"nctId":"NCT03556956","phase":"PHASE2, PHASE3","title":"Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AB Science","startDate":"2015-07","conditions":"Colorectal Cancer Metastatic","enrollment":219},{"nctId":"NCT04624464","phase":"","title":"Assessing the Impact of Antimicrobial Exposure and Infection Control Measures on the Spread of VRE","status":"UNKNOWN","sponsor":"University Hospital of Cologne","startDate":"2019-01-01","conditions":"VRE Infection, Antibiotic Resistant Infection","enrollment":170},{"nctId":"NCT04621487","phase":"NA","title":"Quadruple vs Tailored Therapy in the Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"University of Split, School of Medicine","startDate":"2019-01-15","conditions":"Helicobacter Pylori Infection","enrollment":80},{"nctId":"NCT02024555","phase":"PHASE2","title":"Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-03","conditions":"Sarcoidosis; Antimycobacterial Therapy","enrollment":97},{"nctId":"NCT04438629","phase":"","title":"Evaluation of Immune Response in COVID-19 Patients","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2020-03-26","conditions":"Allergy and Immunology, Infection Viral","enrollment":80},{"nctId":"NCT03226366","phase":"","title":"Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM)","status":"COMPLETED","sponsor":"Intermountain Health Care, Inc.","startDate":"2015-05-16","conditions":"Septic Shock, Sepsis","enrollment":3230},{"nctId":"NCT04402203","phase":"PHASE2, PHASE3","title":"Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh","status":"UNKNOWN","sponsor":"Bangladesh Medical Research Council (BMRC)","startDate":"2020-05","conditions":"COVID-19, Favipiravir (Favipira)","enrollment":50},{"nctId":"NCT02491047","phase":"NA","title":"Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo I, II, IIIA and IIIB Tibial Open Fractures","status":"COMPLETED","sponsor":"PolyPid Ltd.","startDate":"2015-10","conditions":"Tibial Fractures, Open Fractures","enrollment":51},{"nctId":"NCT03726099","phase":"PHASE4","title":"Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-03-15","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT02055729","phase":"","title":"Changes in Bacterial Flora Among Patients With Pelvic Bedsores: a Prospective Pilot Study","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2015-05-11","conditions":"Bedsore","enrollment":55},{"nctId":"NCT01358734","phase":"PHASE2","title":"A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2012-04-27","conditions":"Acute Myeloid Leukemia, Acute Myelogenous Leukemia","enrollment":88},{"nctId":"NCT03583476","phase":"","title":"The Impact of Antibiotics MIC Value on the Efficacy of Treatment Regimens for Helicobacter Pylori Infection.","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2018-04-01","conditions":"Helicobacter Pylori Infection","enrollment":1821},{"nctId":"NCT03532464","phase":"PHASE4","title":"Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2018-07-01","conditions":"Chlamydia Trachomatis Infection, Vaginal Infection, Anal Infection","enrollment":460},{"nctId":"NCT02235285","phase":"NA","title":"Asian Outcomes of Primary Breast Augmentation","status":"COMPLETED","sponsor":"Winners Clinic","startDate":"2010-01","conditions":"Breast Augmentation","enrollment":162},{"nctId":"NCT01489839","phase":"","title":"Biomarkers of Periodontal Disease Progression","status":"COMPLETED","sponsor":"The Forsyth Institute","startDate":"2012-01","conditions":"Periodontal Disease","enrollment":157},{"nctId":"NCT03039244","phase":"NA","title":"Evaluation of Antimicrobial Photodynamic Therapy as an Adjunct to Periodontal Treatment in Smokers","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2014-09-01","conditions":"Chronic Periodontitis","enrollment":20},{"nctId":"NCT02545452","phase":"PHASE1","title":"Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-15","conditions":"Endometriosis","enrollment":52},{"nctId":"NCT02576236","phase":"NA","title":"Therapeutic Trial Comparing Triple Therapy Guided by the PCR Detection of Clarithromycin Resistance vs Empiric Concomitant Quadruple Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05","conditions":"H Pylori Infection Eradication, Antibiotics Therapeutic Strategies, H Pylori Eradication","enrollment":2500},{"nctId":"NCT03113747","phase":"PHASE1, PHASE2","title":"Allogeneic ADSCs and Platelet-Poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds (ADSCs-BWs)","status":"UNKNOWN","sponsor":"A.A. Partners, LLC","startDate":"2015-03-25","conditions":"Second- or Third-degree Burns","enrollment":20},{"nctId":"NCT02974348","phase":"PHASE3","title":"Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa","status":"COMPLETED","sponsor":"University of Bamenda","startDate":"2013-01","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":300},{"nctId":"NCT02466919","phase":"PHASE4","title":"Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients","status":"COMPLETED","sponsor":"Chung-Tai Wu","startDate":"2014-05","conditions":"Helicobacter Pylori Infection","enrollment":114},{"nctId":"NCT02759029","phase":"NA","title":"Development of Treatment Algorithm for Eradication of Helicobacter Pylori Based on Antibiotic Susceptibility Test","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2016-03","conditions":"Helicobacter Pylori Infection","enrollment":123},{"nctId":"NCT00332163","phase":"PHASE2","title":"Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04","conditions":"Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities","enrollment":95},{"nctId":"NCT02503904","phase":"PHASE2, PHASE3","title":"Tumescent Antibiotic Delivery for Prevention of Surgical Site Infection","status":"UNKNOWN","sponsor":"Klein, Jeffrey A., M.D.","startDate":"2015-10","conditions":"Surgical Site Infections, Venous Thromboembolism","enrollment":400},{"nctId":"NCT01103323","phase":"PHASE3","title":"Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-04","conditions":"Metastatic Colorectal Cancer","enrollment":760},{"nctId":"NCT00153881","phase":"PHASE1","title":"Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2000-02","conditions":"Esophageal Neoplasms","enrollment":44},{"nctId":"NCT01848535","phase":"NA","title":"Effect of GOS Supplementation on Amoxicillin-treated Gut Microbiota From Healthy Adults","status":"COMPLETED","sponsor":"Wageningen University","startDate":"2013-05","conditions":"Colonic Diseases [C06.405.469.158]","enrollment":12},{"nctId":"NCT01598402","phase":"PHASE2, PHASE3","title":"Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Head and Neck Cancer to Prevent Aspiration Pneumonia","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2011-12","conditions":"Head and Neck Cancer","enrollment":106},{"nctId":"NCT01265069","phase":"PHASE4","title":"Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-11","conditions":"Helicobacter Pylori Infection","enrollment":204},{"nctId":"NCT01061437","phase":"PHASE3","title":"S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-06","conditions":"Helicobacter Pylori Infection","enrollment":1859},{"nctId":"NCT01572597","phase":"PHASE4","title":"Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2011-06","conditions":"Bacterial Infection Due to Helicobacter Pylori (H. Pylori)","enrollment":120},{"nctId":"NCT01566643","phase":"PHASE4","title":"Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2011-01","conditions":"Helicobacter Pylori Infection","enrollment":231},{"nctId":"NCT01259219","phase":"PHASE1","title":"Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra","status":"UNKNOWN","sponsor":"Harriet Shezi Children's Clinic","startDate":"2010-11","conditions":"Children With Confirmed HIV Infection, Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose, Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Concomitant Antibiotic Therapy","genericName":"Concomitant Antibiotic Therapy","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Concomitant antibiotic therapy works by simultaneously administering multiple antibiotics to target bacteria through different mechanisms, reducing resistance and improving treatment efficacy. Used for Serious bacterial infections (specific indication dependent on Phase 3 trial design).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}